Psoriasis

Song stressed the need for careful therapy selection in patients with comorbid conditions to avoid exacerbating health issues.

Historically, research and clinical practice often have overlooked the distinct manifestations and treatment needs of patients with skin of color who have psoriasis.

E. James Song, MD, FAAD, provides key takeaways on the treatment of patients with plaque psoriasis, highlighting ways to define treatment success and the effect of adverse events on long-term treatment choices.

A dermatologist shares perspectives on patient-specific factors that impact treatment decisions in plaque psoriasis.

The new delivery systems for bimekizumab-bkzx represent an upgrade over previous 1 mL options, reducing the frequency of injections required.

Omar Noor, MD, FAAD, hosted a live Case-Based Roundtable discussion with local dermatology clinicians to discuss 2 patients with plaque psoriasis and what would be the ideal topical treatment for each.

Researchers behind the study emphasized the urgent need to enhance the diagnostic skills of primary care practitioners to improve early detection of psoriasis.

Otulfi from Formycon and Fresenius Kabi was approved simultaneously in the US and the European Union. In the US, it will launch in February 2025.

An expert on plaque psoriasis provides an overview of systemic therapy options and provides clinical insights on patient monitoring practices and best courses of action when treatment response isn’t sustained.

E. James Song, MD, FAAD, presents a case of a 58-year-old patient with location-specific mild-to-moderate plaque psoriasis.

The IL-17 inhibitor demonstrated biologic-level efficacy in moderate to severe plaque psoriasis.

Over 70% of patients achieved clear or minimal skin by week 48, with a 90% retention rate in diverse patients with PsO.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.

A dermatologist provides clinical insights on navigating dose escalation and insurance barriers for patients receiving treatment for plaque psoriasis.

Continuing discussion on a case of a 45-year-old patient with plaque psoriasis, E. James Song, MD, FAAD, discusses management strategies for patients with mild-to-moderate plaque psoriasis.

Enhanced education can reduce uncertainty among both patients and providers, with pharmacists playing a key role as primary sources of patient information.

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

The company plans to release full 52-week OLE data for ESK-001 in early 2025, building on positive interim results.

Focusing on treatment paradigms in plaque psoriasis, E. James Song, MD, FAAD, provides insights on phosphodiesterase inhibitors 4 (PDE-4) and their role in the therapeutic landscape.

E. James Song, MD, FAAD, presents the case of a 45-year-old woman with plaque psoriasis who lives in a rural area, introducing a discussion on clinical telemedicine practices.

The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.